We characterized disease progression over 48 weeks among boys receiving deflazacort versus prednisone/prednisolone placebo arm treatment in two recent Duchenne muscular dystrophy (DMD) clinical trials. Ambulatory boys with DMD receiving placebo in the Phase 3 ataluren (n=115) and tadalafil (n=116) trials were included. The trials required ≥ 6 months of prior corticosteroid use and stable baseline dosing. Associations between corticosteroid and 48-week changes in ambulatory function were estimated using mixed models. Adjusted differences between corticosteroid groups were pooled in a meta-analysis. In the meta-analysis, deflazacort-treated patients versus prednisone/prednisolone-treated patients experienced, on average, lower declines of 28.3 meters on six-minute walk distance [95% confidence interval: (5.7, 50.9)], 2.9 seconds on rise from supine, [(0.9, 4.9)], 2.3 seconds on 4 stair climb [(0.5, 4.1)], and 2.9 points [(0. 1, 5.8)] on the North Star Ambulatory Assessment linearized score. Deflazacort-treated patients experienced significantly lower functional decline over 48 weeks.

Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials

Vita G;
2020-01-01

Abstract

We characterized disease progression over 48 weeks among boys receiving deflazacort versus prednisone/prednisolone placebo arm treatment in two recent Duchenne muscular dystrophy (DMD) clinical trials. Ambulatory boys with DMD receiving placebo in the Phase 3 ataluren (n=115) and tadalafil (n=116) trials were included. The trials required ≥ 6 months of prior corticosteroid use and stable baseline dosing. Associations between corticosteroid and 48-week changes in ambulatory function were estimated using mixed models. Adjusted differences between corticosteroid groups were pooled in a meta-analysis. In the meta-analysis, deflazacort-treated patients versus prednisone/prednisolone-treated patients experienced, on average, lower declines of 28.3 meters on six-minute walk distance [95% confidence interval: (5.7, 50.9)], 2.9 seconds on rise from supine, [(0.9, 4.9)], 2.3 seconds on 4 stair climb [(0.5, 4.1)], and 2.9 points [(0. 1, 5.8)] on the North Star Ambulatory Assessment linearized score. Deflazacort-treated patients experienced significantly lower functional decline over 48 weeks.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3145121
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 35
social impact